Last 44 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -20.14 | — | — | — | — | — | — | 14.23 | — | — | — | — | 0.86 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.80 | 2.63 | 2.01 | 2.94 | 2.52 | 2.79 | 2.54 | 1.59 | 1.98 | 1.90 | 1.40 | 1.82 | 0.42 | 0.42 | 0.57 | 0.53 | 0.67 | 0.89 | 0.90 | 1.02 | — |
| — | -5.6% | -21.0% | +84.7% | +27.1% | +46.8% | +82.0% | -12.8% | +375.3% | +355.3% | +143.8% | +242.2% | -37.9% | -53.3% | -36.2% | -47.6% | — | — | — | — | — | |
| P/B Ratio | 3.44 | 6.06 | 4.15 | 5.93 | 6.86 | 8.69 | 6.19 | 4.32 | 10.62 | 9.98 | 5.61 | 5.47 | 3.32 | 5719.42 | 3.73 | 2.00 | 1.66 | 1.88 | 2.02 | 1.69 | — |
| — | -30.2% | -32.9% | +37.4% | -35.4% | -13.0% | +10.3% | -21.1% | +220.1% | -99.8% | +50.4% | +172.9% | +100.4% | +304728.5% | +84.9% | +18.3% | — | — | — | — | — | |
| P/FCF | — | — | 11.01 | — | — | — | — | 9.73 | — | — | — | — | 0.77 | 1.80 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 96.83 | 34.13 | — | 73.72 | — | — | — | 7.11 | — | — | — | — | 0.46 | — | — | — | — | — | 94.65 | — | — |
| — | — | — | +937.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 79.87 | — | — | — | — | — | 9.53 | — | — | — | — | 0.48 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 66.8% | 54.0% | 59.5% | 67.4% | 60.0% | 55.4% | 83.6% | 63.9% | 56.0% | 47.7% | 60.6% | 81.4% | 54.8% | 47.2% | 51.7% | 55.2% | 58.3% | 64.8% | 58.8% | 58.4% |
| — | +11.3% | -2.6% | -28.8% | +5.5% | +7.2% | +16.2% | +38.0% | -21.5% | +2.2% | +1.0% | +17.3% | +47.5% | -6.0% | -27.2% | -12.1% | -5.4% | -1.1% | +2.0% | -14.6% | -13.6% | |
| Operating Margin | -13.2% | 2.5% | -9.3% | -2.8% | -8.7% | -19.2% | -25.3% | 16.4% | -19.8% | -19.7% | -77.4% | -13.8% | 49.9% | -44.6% | -78.3% | -62.6% | -58.9% | -39.0% | -3.8% | -51.7% | -64.5% |
| — | +112.9% | +63.1% | -116.8% | +56.2% | +2.8% | +67.3% | +218.9% | -139.6% | +55.8% | +1.1% | +78.0% | +184.8% | -14.1% | -1953.8% | -21.1% | +8.7% | +56.6% | -169.8% | -295.7% | -445.6% | |
| Net Margin | -18.5% | -1.7% | -14.0% | -7.8% | -13.1% | -25.3% | -31.0% | 11.2% | -16.3% | -22.6% | -80.1% | -14.0% | 48.6% | -48.7% | -83.0% | -66.7% | -62.5% | -41.2% | -5.9% | -124.2% | -54.3% |
| — | +93.3% | +54.9% | -169.4% | +19.6% | -11.8% | +61.3% | +179.5% | -133.6% | +53.5% | +3.4% | +78.9% | +177.7% | -18.3% | -1303.1% | +46.3% | -15.2% | +47.0% | -336.6% | -781.1% | -521.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -1.0% | -7.1% | -4.3% | -10.3% | -18.6% | -19.6% | 9.8% | -21.5% | -27.7% | -62.7% | -11.4% | 193.2% | -223.1% | -82.8% | -49.3% | -33.1% | -19.8% | -3.3% | -143.4% | — |
| — | +94.7% | +63.7% | -144.0% | +52.3% | +32.9% | +68.8% | +186.4% | -111.1% | +87.6% | +24.3% | +77.0% | +684.4% | -1029.6% | -2409.0% | +65.6% | — | +92.1% | — | -809.9% | — | |
| ROA | -13.1% | -0.3% | -2.4% | -1.4% | -2.8% | -4.6% | -4.9% | 2.1% | -3.7% | -5.1% | -14.6% | -3.0% | 24.8% | -10.1% | -10.1% | -10.0% | -9.1% | -6.4% | -1.3% | -23.3% | -13.2% |
| — | +92.8% | +51.4% | -165.8% | +24.7% | +10.4% | +66.1% | +170.2% | -114.9% | +49.5% | -44.4% | +69.9% | +372.1% | -57.2% | -698.4% | +57.3% | +30.9% | +66.3% | — | -2377.3% | — | |
| ROIC | -20.9% | 1.1% | -3.6% | -1.1% | -4.5% | -8.7% | -9.8% | 9.6% | -22.0% | -26.1% | -87.5% | -92.9% | — | -66.3% | -61.3% | -78.6% | -49.0% | -32.6% | -15.1% | -840.7% | -11566.5% |
| — | +112.9% | +63.1% | -111.7% | +79.4% | +66.8% | +88.8% | +110.3% | — | +60.7% | -42.7% | -18.2% | — | -103.5% | -306.4% | +90.6% | +99.6% | +93.1% | -128.8% | -47390.7% | -1081583.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.80 | 0.80 | 0.83 | 0.80 | 0.98 | 1.31 | 1.17 | 1.28 | 1.93 | 2.02 | 1.37 | 0.87 | 0.01 | 2019.20 | 3.38 | 1.35 | 0.76 | 0.61 | 0.36 | 0.02 | — |
| — | -39.4% | -29.3% | -37.8% | -49.3% | -35.0% | -14.8% | +47.0% | +25474.7% | -99.9% | -59.4% | -35.6% | -99.0% | +330090.9% | +842.5% | +6147.7% | — | — | — | -97.8% | — | |
| Debt / EBITDA | — | 17.92 | — | 39.37 | — | — | — | 7.94 | — | — | — | — | 0.01 | — | — | — | — | — | 98.35 | — | — |
| — | — | — | +395.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.79 | 1.59 | 1.72 | 1.79 | 1.42 | 1.27 | 1.34 | 1.37 | 1.38 | 1.36 | 1.21 | 1.35 | 0.92 | 0.70 | 0.79 | 1.16 | 1.31 | 1.40 | 1.48 | 1.64 | 1.12 |
| — | +25.6% | +27.9% | +30.4% | +2.5% | -6.9% | +11.2% | +1.6% | +50.3% | +94.6% | +52.9% | +16.0% | -29.7% | -49.9% | -46.7% | -29.0% | +17.2% | +15.9% | — | +30.4% | — | |
| Quick Ratio | 1.53 | 1.41 | 1.47 | 1.53 | 1.12 | 0.95 | 1.03 | 0.96 | 1.03 | 1.08 | 0.94 | 1.10 | 0.69 | 0.52 | 0.62 | 0.95 | 1.06 | 1.13 | 1.22 | 1.45 | 0.92 |
| — | +48.8% | +42.7% | +59.4% | +8.8% | -11.9% | +10.2% | -13.1% | +48.6% | +106.9% | +51.7% | +16.2% | -34.5% | -53.9% | -49.3% | -34.3% | +14.8% | +28.0% | — | +19.9% | — | |
| Interest Coverage | -2.07 | 0.67 | -1.50 | -0.34 | -1.47 | -2.99 | -3.57 | 2.90 | -2.15 | -4.97 | -18.05 | -83.04 | 64.00 | -10.06 | -14.59 | -16.23 | -17.01 | -15.72 | -2.28 | -1.65 | -0.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DERM stock.
Journey Medical Corporation's current P/E is -20.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Journey Medical Corporation's current operating margin is -13.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Journey Medical Corporation's business trajectory between earnings reports.